Geode Capital Management LLC Acquires 107,151 Shares of scPharmaceuticals Inc. (NASDAQ:SCPH)

Geode Capital Management LLC grew its position in shares of scPharmaceuticals Inc. (NASDAQ:SCPH - Free Report) by 16.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 750,493 shares of the company's stock after buying an additional 107,151 shares during the period. Geode Capital Management LLC owned approximately 1.50% of scPharmaceuticals worth $2,657,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Legato Capital Management LLC bought a new position in scPharmaceuticals during the fourth quarter worth about $37,000. China Universal Asset Management Co. Ltd. bought a new position in shares of scPharmaceuticals during the fourth quarter worth approximately $38,000. Virtu Financial LLC acquired a new stake in shares of scPharmaceuticals in the third quarter valued at approximately $46,000. SG Americas Securities LLC bought a new stake in shares of scPharmaceuticals in the fourth quarter valued at approximately $66,000. Finally, Corebridge Financial Inc. boosted its stake in shares of scPharmaceuticals by 29.0% in the fourth quarter. Corebridge Financial Inc. now owns 19,586 shares of the company's stock valued at $69,000 after buying an additional 4,406 shares during the period. Institutional investors own 89.52% of the company's stock.

scPharmaceuticals Trading Up 3.8 %

Shares of SCPH stock traded up $0.10 during mid-day trading on Friday, reaching $2.63. 116,780 shares of the stock traded hands, compared to its average volume of 356,258. The company has a market cap of $132.00 million, a price-to-earnings ratio of -1.38 and a beta of 0.38. The company has a quick ratio of 6.89, a current ratio of 8.08 and a debt-to-equity ratio of 1.66. The stock's fifty day simple moving average is $2.74 and its two-hundred day simple moving average is $3.31. scPharmaceuticals Inc. has a 1-year low of $1.94 and a 1-year high of $5.65.

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) last announced its earnings results on Wednesday, March 19th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.05. scPharmaceuticals had a negative return on equity of 244.93% and a negative net margin of 264.60%. The business had revenue of $12.15 million for the quarter, compared to analysts' expectations of $12.08 million. On average, research analysts anticipate that scPharmaceuticals Inc. will post -1.53 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Maxim Group dropped their price objective on scPharmaceuticals from $20.00 to $12.00 and set a "buy" rating for the company in a report on Thursday, March 20th. HC Wainwright reiterated a "buy" rating and set a $18.00 price objective on shares of scPharmaceuticals in a research note on Thursday, March 20th.

scPharmaceuticals Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.